| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 10 Sep 2026 |
8-K: Regulation FD Disclosure
This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and cli... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Prelude Therapeutics Incorporated (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were approved by the Company's stockholders: |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) |
| 21 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Represent... |
| 20 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and cli... |
| 15 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
WILMINGTON, Del., Apr. 15, 2026 (GLOBE NEWSWIRE) – Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join... |
| 12 Mar 2026 |
8-K: Other Events
We have acted as counsel to Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), in connection with the offer and sale by the Company, to or through Jefferies LLC, as the sales agent (the “Sales Agent”), from time t... |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 |
| 03 Feb 2026 |
8-K: Regulation FD Disclosure
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure
This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and cli... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 |
| 04 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
Forward Looking Statements & Disclaimers This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to,an... |
| 17 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) – Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today... |
| 19 Sep 2025 |
8-K: Other Events
As previously disclosed on March 28, 2025, Prelude Therapeutics Incorporated (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March 27, 2025, notifying the Company ... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 |
| 13 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On June 11, 2025, upon the recommendation of the Nominating and Corporate Governance Committee (the “Governance Committee”) of the Board of Directors (the “Board”) of Prelude Therapeutics Incorporated (the “Company”), the Board appointed... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 |
| 25 Apr 2025 |
8-K: Other Events
Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development |
Loading...